<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01509144</url>
  </required_header>
  <id_info>
    <org_study_id>2010-023693-39</org_study_id>
    <nct_id>NCT01509144</nct_id>
  </id_info>
  <brief_title>EuroNeut41: Safety &amp; Immunogenicity of Immunisations With HIV Vaccine</brief_title>
  <official_title>Phase 1, Randomised, Single-centre, Observer-blind Clinical Trial of Safety and Immunogenicity of Nasal-prime and Intramuscular Boost Immunisation With EN41-FPA2 HIV Vaccine in Healthy Female Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PX'Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>PX'Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives:&#xD;
&#xD;
        -  To assess the safety of three priming immunisations by nasal route followed by two&#xD;
           booster immunisations by intramuscular route&#xD;
&#xD;
        -  To assess immunogenicity responses induced by the vaccine.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>• Safety of 5 EN41-FPA2 immunisations Primary Endpoints: AEs and IgG and IgA responses to EN41-FPA2</measure>
    <time_frame>up to 28 days after the final immunisation</time_frame>
    <description>•Safety - Grade 3 or above adverse event. Any grade of adverse event that results in a clinical decision to discontinue further immunisations - Any grade of adverse event that occurs in a volunteer that has received at least one immunisation • Immunogenicity: Proportion of individuals mounting a serum IgG response to EN41-FPA2 at any time point up to 28 days after the final immunisation with 3 fold increase from pre-immunisation baseline sample taken at visit 2, week 0, priming #1. If no serum sample is available at this time point, serum taken at visit 1, screening may be substituted.&quot;</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>nasal active low dose + IM active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 1 Nasal vaccine - Low-dose (20 µg in 40 µL) IM vaccine (200 µg in 400 µL)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nasal active mid dose + IM active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 2 Nasal vaccine - Mid-dose (100 µg in 200 µL) IM vaccine (200 µg in 400 µL)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nasal active full dose + IM active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 3 Nasal vaccine - Full-dose (200 µg in 400 µL) IM vaccine (200 µg in 400 µL)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nasal placebo + IM active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 4 Nasal Placebo - 400 µL IM vaccine (200 µg in 400 µL)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nasal placebo + IM placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group 5 Nasal placebo - 40 µL in Cohort 1 / 200 µL in Cohort 2 IM placebo (400 µL)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>EN41-FPA2 HIV vaccine</intervention_name>
    <description>Group 1 Nasal vaccine - Low-dose (20 µg in 40 µL) IM vaccine (200 µg in 400 µL)</description>
    <arm_group_label>nasal active low dose + IM active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>EN41-FPA2 HIV vaccine</intervention_name>
    <description>Group 2 Nasal vaccine - Mid-dose (100 µg in 200 µL) IM vaccine (200 µg in 400 µL)</description>
    <arm_group_label>nasal active mid dose + IM active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>EN41-FPA2 HIV vaccine</intervention_name>
    <description>Group 3 Nasal vaccine - Full-dose (200 µg in 400 µL) IM vaccine (200 µg in 400 µL)</description>
    <arm_group_label>nasal active full dose + IM active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>EN41-FPA2 HIV vaccine</intervention_name>
    <description>Group 4 Nasal Placebo - 400 µL IM vaccine (200 µg in 400 µL)</description>
    <arm_group_label>nasal placebo + IM active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Na Cl Placebo vaccine</intervention_name>
    <description>Group 5 Nasal placebo - 40 µL in Cohort 1 / 200 µL in Cohort 2 IM placebo (400 µL)</description>
    <arm_group_label>nasal placebo + IM placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Women aged between 18 and 55 years on the day of screening&#xD;
&#xD;
          2. Available for a maximal study duration of 12/13 months from the inclusion&#xD;
&#xD;
          3. Willing and able to give written informed consent&#xD;
&#xD;
          4. At low risk of HIV infection and willing to remain so for the duration of the study&#xD;
             defined as:&#xD;
&#xD;
               -  no history of injecting drug use in the previous ten years&#xD;
&#xD;
               -  no gonorrhoea or syphilis in the last six months&#xD;
&#xD;
               -  no high risk partner (e.g. injecting drug use, HIV positive partner) either&#xD;
                  currently or within the past six months&#xD;
&#xD;
               -  no unprotected anal intercourse in the last six months, outside a relationship&#xD;
                  with a regular partner known to be HIV negative&#xD;
&#xD;
               -  no unprotected vaginal intercourse in the last six months outside a relationship&#xD;
                  with a regular known HIV negative partner&#xD;
&#xD;
               -  not had unprotected sex with someone from a region where HIV is more common (e.g&#xD;
                  Sub-Saharan African, Caribbean, South East Asia) outside a relationship with a&#xD;
                  regular known HIV negative partner&#xD;
&#xD;
          5. Negative HIV 1/2 antibody/antigen test at screening&#xD;
&#xD;
          6. If heterosexually active female, using an effective method of contraception with&#xD;
             partner (combined oral contraceptive pill; injectable or implanted contraceptive; use&#xD;
             of condoms incorporating spermicide if using these; physiological or anatomical&#xD;
             sterility) from 14 days prior to the first vaccination until 6 months after the last,&#xD;
             and willing to undergo urine pregnancy tests prior to each vaccination and blood&#xD;
             pregnancy test at screening and final follow up.&#xD;
&#xD;
          7. Agree, to abstain from medications or other agents that are applied via the nasal&#xD;
             route from 24 hours prior to each nasal vaccine dosing through to the safety&#xD;
             assessment 1week later&#xD;
&#xD;
          8. Agree to abstain from donating blood during their participation in the trial&#xD;
&#xD;
          9. Registered with GP and medical history available for 12 months before dosing&#xD;
&#xD;
         10. Satisfactory response received from General Practitioner relating to medical history&#xD;
             before randomization.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or lactating, or planning to get pregnant within the next year&#xD;
&#xD;
          2. Positive alcohol test&#xD;
&#xD;
          3. Positive drugs of abuse test&#xD;
&#xD;
          4. Clinically relevant abnormality on history or examination:&#xD;
&#xD;
               -  central nervous system disorder or disease, including&#xD;
&#xD;
               -  history of grand-mal epilepsy&#xD;
&#xD;
               -  cranial nerve palsies&#xD;
&#xD;
               -  severe eczema&#xD;
&#xD;
               -  severe epistaxis requiring surgical intervention or blood transfusion&#xD;
&#xD;
               -  clinically significant liver disease&#xD;
&#xD;
               -  clinically significant haematological, metabolic, gastrointestinal, renal,&#xD;
                  psychiatric or cardio-pulmonary disorders&#xD;
&#xD;
               -  ongoing infection;&#xD;
&#xD;
               -  autoimmune disease, immunodeficiency or use of immunosuppressive agents in&#xD;
                  preceding 3 months prior to dosing&#xD;
&#xD;
               -  using inhaled cortico-steroids and intranasal medications&#xD;
&#xD;
          5. Known or suspected history of clinically relevant nasal surgery, injury, nasal polyps&#xD;
             or cleft palate, or a condition likely to require regular intranasal medication, which&#xD;
             in the opinion of the investigator might interfere with intranasal vaccine&#xD;
             administration&#xD;
&#xD;
          6. Known hypersensitivity to any component of the vaccine formulations used in this trial&#xD;
             or have severe or multiple allergies&#xD;
&#xD;
          7. History of severe local or general reaction to vaccination defined as&#xD;
&#xD;
               -  local: extensive, indurated redness and swelling involving most of the&#xD;
                  antero-lateral thigh or the major circumference of the arm, not resolving within&#xD;
                  72 hours&#xD;
&#xD;
               -  general: fever &gt; 39.5°C within 48 hours; anaphylaxis; bronchospasm; laryngeal&#xD;
                  oedema; collapse; convulsions or encephalopathy within 72 hours&#xD;
&#xD;
          8. Receipt of live attenuated vaccine within 60 days or other vaccine within 14 days of&#xD;
             scheduled study vaccine dosing&#xD;
&#xD;
          9. Receipt of an experimental vaccine containing HIV envelope proteins at any time in the&#xD;
             past&#xD;
&#xD;
         10. Receipt of blood products or immunoglobin within 4 months of screening&#xD;
&#xD;
         11. Participation in another trial of a medicinal product, completed less than 90 days&#xD;
             prior to Visit 2 and planned participation in another clinical trial during the&#xD;
             present trial&#xD;
&#xD;
         12. HIV 1/2 antibody/antigen positive or indeterminate on screening&#xD;
&#xD;
         13. Positive for hepatitis B surface antigen, hepatitis C antibody or serology indicating&#xD;
             active syphilis requiring treatment&#xD;
&#xD;
         14. Clinically significant routine laboratory parameters.&#xD;
&#xD;
         15. Unable to read and speak English to a fluency level adequate for the full&#xD;
             comprehension of procedures required in participation and consent.&#xD;
&#xD;
         16. Unlikely to comply with protocol&#xD;
&#xD;
         17. History of drug or alcohol abuse or regular using of drugs, or who test positive in&#xD;
             drugs of abuse and alcohol test at screening or admission&#xD;
&#xD;
         18. Has a condition, or is on regular medication (other than paracetamol, multivitamin,&#xD;
             E45, or over the counter remedies) which in the opinion of the investigator is not&#xD;
             suitable for participation in the study&#xD;
&#xD;
         19. Any local vaginal, cervical or gynaecological condition which may interfere with&#xD;
             collection or interpretation of data collected through vaginal samples.&#xD;
&#xD;
         20. Using any Intra Uterine Contraceptive Device; as there is a risk of dislodging,&#xD;
             displacing or removing the device when pulling or removing Softcup used for vaginal&#xD;
             sampling.&#xD;
&#xD;
         21. Clinically significant abnormality on ECG performed at the screening visit&#xD;
&#xD;
         22. Any condition that, in the investigator's opinion, compromises the volunteer's ability&#xD;
             to meet protocol requirements or to complete the study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Surrey Clinical Research Centre University of Surrey</name>
      <address>
        <city>Guildford</city>
        <state>Surrey</state>
        <zip>GU2 7XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <study_first_submitted>January 4, 2012</study_first_submitted>
  <study_first_submitted_qc>January 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2012</study_first_posted>
  <last_update_submitted>May 20, 2014</last_update_submitted>
  <last_update_submitted_qc>May 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Safety of this HIV vaccine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

